Smartwatch with heart rate monitor icon on colorful diagonal striped background
Medtech Case Study

Researchers and Patient Group Collaborate on Device for Multiple Sclerosis Patients

Using Patient Engagement to Improve Exoskeleton Product Development and Clinical Trial Design for Multiple Sclerosis Patients
 

Source
The PFMD Book of Good Practices, Third Edition

Link 
Consulting a Patient and Carer Group on the Delivery of Exoskeleton-Assisted Walking to Aid Cardiovascular Fitness in Patients with Gait Problems Due to Multiple Sclerosis
 

Description of Case Study

Researchers at the National Institute for Health and Care Research Sheffield Biomedical Research Centre engaged people with multiple sclerosis (MS) and their caregivers through an established patient advisory group to refine the design and delivery of a clinical study evaluating powered, exoskeleton-assisted walking. The purpose of the engagement was to determine whether the intervention would be acceptable, safe, feasible, and practical for routine use and to improve the study protocol so it better reflected the needs, concerns, and experiences of people with moderate to severe mobility limitations.
 

Quick Facts

Organization name: Sheffield Biomedical Research Centre
Organization type: academic or other nonprofit researcher
Product category: therapeutic device or technology
Region(s) of patient engagement activities: Europe: United Kingdom
Total product life cycle stage(s): discovery/preclinical, clinical/testing,
evaluation/authorization

 

Product Type(s)

medical device:

  • therapeutic device
     

Product Medical Specialty Area(s)

  • neurology
  • physical medicine
     

Stakeholders

  • patients and caregivers, patient organizations
  • providers (clinicians, hospital/health system administrators)
  • other: academic and other nonprofit researchers
     

Methods and Sources of Patient Input

  • patient advisory boards
  • interviews/focus groups/surveys
     

Impact of Patient Engagement

  • Improved study protocol: Patient and caregiver feedback led researchers to modify the study protocol before the trial began.
  • Enhanced safety measures: Input on fear of falling resulted in additional practice sessions and protocol revisions, therapist supervision, and other safety features during exoskeleton-assisted walking.
  • More patient-centered outcomes: The study was refined to assess outcomes important to patients, including safety, acceptability, usability, and practicality for regular use.
  • Greater real-world relevance: Patient perspectives ensured the study reflected the realities of living with moderate to severe mobility limitations rather than relying solely on clinical assumptions.
  • Ongoing patient partnership: Researchers returned to the advisory group to share updates and demonstrate how patient feedback informed the study.
     

Lessons Learned

  • Engage patients early: A key lesson was that involving patients and caregivers early in the research process helped ensure that studies addressed meaningful and relevant questions for the target population.
  • Look beyond clinical outcomes: Input from people living with MS helped researchers consider not only clinical effectiveness but also whether the intervention was practical, acceptable, and safe for routine use.
  • Address real-world concerns: The case study also highlighted the importance of evaluating new technologies within the context of everyday life and real-world disease burden. By incorporating patient perspectives, the team better understood factors that could influence participation, adherence, and long-term use, strengthening the relevance of the research and the potential value of the exoskeleton as a rehabilitation tool.